Expansion-minded CRO PSI has opened up shop in Israel, expanding its global reach to cover a market the company believes is poised for growth.
After years of working in Israel through partners, the Swiss-headquartered PSI has established a permanent operation there, building on its experience running cancer, infectious disease and CNS-related studies in Israel.
The CRO has appointed Ronit Pakula, a veteran of PPD and Quintiles ($Q), to lead its clinical operations team in the country.
The move follows years of expansion for PSI, as the CRO has established offices in Austria, Italy, South Africa, India and the U.S. over the past four years.
Competing in the global market for clinical services, PSI touts its stability. The company claims to have a staff turnover of just 5%, well below the industry average of around 20%, as reported by HR+ Survey Solutions. PSI says its repeat business rate hovers around 90%, billing itself as a "no-nonsense" partner for drugmakers around the globe.
- read the statement